Insights into Endothelin Receptors in Pulmonary Hypertension
Pulmonary hypertension (PH) is a disease which affects the cardiopulmonary system; it is defined as a mean pulmonary artery pressure (mPAP) > 20 mmHg as measured by right heart catheterization at rest, and is caused by complex and diverse mechanisms. In response to stimuli such as hypoxia and ischemia, the expression and synthesis of endothelin (ET) increase, leading to the activation of various signaling pathways downstream of it and producing effects such as the induction of abnormal vascular proliferation during the development of the disease. This paper reviews the regulation of endothelin receptors and their pathways in normal physiological processes and disease processes, and describes the mechanistic roles of ET receptor antagonists that are currently approved and used in clinical studies. Current clinical researches on ET are focused on the development of multi-target combinations and novel delivery methods to improve efficacy and patient compliance while reducing side effects. In this review, future research directions and trends of ET targets are described, including monotherapy and precision medicine.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:24 |
|---|---|
| Enthalten in: |
International journal of molecular sciences - 24(2023), 12 vom: 16. Juni |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Liu, Ruiqi [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antagonist |
|---|
| Anmerkungen: |
Date Completed 29.06.2023 Date Revised 01.07.2023 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.3390/ijms241210206 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM358746671 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM358746671 | ||
| 003 | DE-627 | ||
| 005 | 20231226075409.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3390/ijms241210206 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1195.xml |
| 035 | |a (DE-627)NLM358746671 | ||
| 035 | |a (NLM)37373355 | ||
| 035 | |a (PII)10206 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Liu, Ruiqi |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Insights into Endothelin Receptors in Pulmonary Hypertension |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 29.06.2023 | ||
| 500 | |a Date Revised 01.07.2023 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Pulmonary hypertension (PH) is a disease which affects the cardiopulmonary system; it is defined as a mean pulmonary artery pressure (mPAP) > 20 mmHg as measured by right heart catheterization at rest, and is caused by complex and diverse mechanisms. In response to stimuli such as hypoxia and ischemia, the expression and synthesis of endothelin (ET) increase, leading to the activation of various signaling pathways downstream of it and producing effects such as the induction of abnormal vascular proliferation during the development of the disease. This paper reviews the regulation of endothelin receptors and their pathways in normal physiological processes and disease processes, and describes the mechanistic roles of ET receptor antagonists that are currently approved and used in clinical studies. Current clinical researches on ET are focused on the development of multi-target combinations and novel delivery methods to improve efficacy and patient compliance while reducing side effects. In this review, future research directions and trends of ET targets are described, including monotherapy and precision medicine | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a antagonist | |
| 650 | 4 | |a drug target | |
| 650 | 4 | |a endothelin receptor | |
| 650 | 4 | |a pulmonary hypertension | |
| 650 | 7 | |a Receptors, Endothelin |2 NLM | |
| 650 | 7 | |a Endothelin Receptor Antagonists |2 NLM | |
| 650 | 7 | |a Endothelins |2 NLM | |
| 650 | 7 | |a Endothelin-1 |2 NLM | |
| 700 | 1 | |a Yuan, Tianyi |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Ranran |e verfasserin |4 aut | |
| 700 | 1 | |a Gong, Difei |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Shoubao |e verfasserin |4 aut | |
| 700 | 1 | |a Du, Guanhua |e verfasserin |4 aut | |
| 700 | 1 | |a Fang, Lianhua |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t International journal of molecular sciences |d 2008 |g 24(2023), 12 vom: 16. Juni |w (DE-627)NLM185552161 |x 1422-0067 |7 nnns |
| 773 | 1 | 8 | |g volume:24 |g year:2023 |g number:12 |g day:16 |g month:06 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3390/ijms241210206 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 24 |j 2023 |e 12 |b 16 |c 06 | ||